Search

Your search keyword '"Trachana, Maria"' showing total 203 results
Start Over Author "Trachana, Maria"
203 results on '"Trachana, Maria"'

1. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.

Author

Lovell, Daniel J, Tzaribachev, Nikolay, Henrickson, Michael, Simonini, Gabriele, Griffin, Thomas A, Alexeeva, Ekaterina, Bohnsack, John F, Zeft, Andrew, Horneff, Gerd, Vehe, Richard K, Staņēviča, Valda, Tarvin, Stacey, Trachana, Maria, Río, Ana Quintero del, Huber, Adam M, Kietz, Daniel, Orbán, Ilonka, Dare, Jason, Foeldvari, Ivan, and Quartier, Pierre

Subjects
JUVENILE idiopathic arthritis, PATIENT safety, RESEARCH funding, SCIENTIFIC observation, ABATACEPT, ANTIRHEUMATIC agents, DESCRIPTIVE statistics, BIOTHERAPY, DRUG efficacy, CONFIDENCE intervals
Abstract

Objective The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. Methods The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Results As of 31 March 2020, 587 patients were enrolled; 569 are included in this analysis (including 134 new users) with 1214.6 patient-years of safety data available. Over 5 years, the incidence rate (IR) per 100 patient-years of follow-up of serious adverse events was 5.52 (95% CI: 4.27, 7.01) and of events of special interest was 3.62 (95% CI: 2.63, 4.86), with 18 serious infections [IR 1.48 (95% CI: 0.88, 2.34)]. As early as month 3, 55.9% of patients achieved cJADAS10 low disease activity and inactive disease (20.3%, 72/354 and 35.6%, 126/354, respectively), sustained over 5 years. Disease activity measures improvement over 5 years across JIA categories. Conclusion Abatacept was well tolerated in patients with JIA, with no new safety signals identified and with well-controlled disease activity, including some patients achieving inactive disease or remission. Trial registration Clinicaltrials.gov, NCT01357668. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index

Author

Rosina, Silvia, primary, Consolaro, Alessandro, additional, Pistorio, Angela, additional, Rebollo-Giménez, Ana, additional, Bracaglia, Claudia, additional, Dolezalova, Pavla, additional, Guilaisne Bernard-Medina, Ana, additional, Herlin, Troels, additional, Trachana, Maria, additional, Vargová, Veronika, additional, Wouters, Carine, additional, Carenini, Laura, additional, Ruperto, Nicolino, additional, and Ravelli, Angelo, additional

Published
2024
Full Text
View/download PDF

12. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

Author

Ruperto, Nicolino, Pistorio, Angela, Oliveira, Sheila, Zulian, Francesco, Cuttica, Ruben, Ravelli, Angelo, Fischbach, Michel, Magnusson, Bo, Sterba, Gary, Avcin, Tadej, Brochard, Karine, Corona, Fabrizia, Dressler, Frank, Gerloni, Valeria, Apaz, Maria T, Bracaglia, Claudia, Cespedes-Cruz, Adriana, Cimaz, Rolando, Couillault, Gerard, Joos, Rik, Quartier, Pierre, Russo, Ricardo, Tardieu, Marc, Wulffraat, Nico, Bica, Blanca, Dolezalova, Pavla, Ferriani, Virginia, Flato, Berit, Bernard-Medina, Ana G, Herlin, Troels, Trachana, Maria, Meini, Antonella, Allain-Launay, Emma, Pilkington, Clarissa, Vargova, Veronika, Wouters, Carine, Angioloni, Simona, and Martini, Alberto

Published
2016
Full Text
View/download PDF

13. Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort

Author

Bustaffa, Marta, primary, Koné-Paut, Isabelle, additional, Ozen, Seza, additional, Amaryan, Gayane, additional, Papadopoulou-Alataki, Efimia, additional, Gallizzi, Romina, additional, Carrabba, Maria, additional, Aviel, Yonatan Butbul, additional, Cantarini, Luca, additional, Alessio, Maria, additional, Anton, Jordi, additional, Obici, Laura, additional, Gok, Faysal, additional, Batu, Ezgi Deniz, additional, Moreno, Estefania, additional, Brogan, Paul, additional, Trachana, Maria, additional, Simonini, Gabriele, additional, Rigante, Donato, additional, Uziel, Yosef, additional, Insalaco, Antonella, additional, Maggio, Maria Cristina, additional, Ruperto, Nicolino, additional, Gattorno, Marco, additional, and Semerano, L Rossi, additional

Published
2023
Full Text
View/download PDF

18. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

Author

Brunner, Hermine I, Holland, Michael J, Beresford, Michael W, Ardoin, Stacy P, Appenzeller, Simone, Silva, Clovis A, Flores, Francisco, Goilav, Beatrice, Aydin, Pinar Ozge Avar, Wenderfer, Scott E, Levy, Deborah M, Ravelli, Angelo, Khubchandani, Raju, Avcin, Tadej, Klein-Gitelman, Marisa S, Ruperto, Nicolino, Feldman, Brian M, Ying, Jun, Battagliotti, Cristina, Brusco, Maria Isabel, Cuttica, Ruben, De Cunto, Carmen, Espada, Graciela, Farfan, Maximiliano, Garay, Stella, Marcantoni, Maria, Marcela, Alvarez, Meiorin, Silvia, Rama, Maria Elena, Russo, Ricardo, Walsh, Carolina Torre, Zamparo, Celso, Adib, Navid, Akikusa, Jonathan, Boros, Christina, Lee, Senq J, Mckay, Damien, Piper, Susan, Joos, Rik, Bica, Blanca, Campos, Leonardo, Cavalcanti, Andre, do Prado, Rogerio, Donner-Maliki, Amanda, Fernandes, Taciana, Fonseca, Adriana, de Almeida, Rozana Gasparello, Guariento, Andressa, Gusman, Catherine, Fiorot, Fernanda Jusan, Oliveira, Sheila Knupp, Len, Claudio, Campos, Lucia M Arruda, Machado, Sandra, Marques, Luciana, de Carvalho, Luciana Martins, Moulin, Rodrigo, Pedroso, Soraya, Pileggi, Gecilmara, Romanelli, Paulo Roberto S, Saad-Magalhaes, Claudia, Sakamoto, Ana, Santos, Maria Carolina, Silva, Marco Felipe, Spelling, Paulo, Sztajnbok, Flavio, Terreri, Maria, Cabral, David, Chedeville, Gaelle, Ellsworth, Janet, Huber, Adam, Tucker, Lori, Houghton, Kristin, Borzutzky, Arturo, Ladino, Mabel, Norambuena, Ximena, Eraso, Ruth, Mosquera, Angela, Velasquez, Monica, Harjacek, Miroslav, Jelusic, Marija, Hermosilla, Cecilia Coto, Dolezalova, Pavla, Nielsen, Susan, Tineo, Carmen, Alegria, Mauricio, Dressler, Frank, Foell, Dirk, Ganser, Gerd, Hinze, Claas, Hufnagel, Markus, Lutz, Thomas, Trauzeddel, Ralf, Boiu, Sorina, Trachana, Maria, Tsitsami, Elena, Cifuentes, Mayra, Orban, Ilonka, Aggarwal, Amita, Sawhney, Sujata, Aviel, Yonatan Butbul, Cimaz, Rolando, Maggio, Maria Cristina, Rumba-Rozenfelde, Ingrid, Hashad, Soad, Lim, Sern Chin, Abud, Carlos, Burgos-Vargas, Ruben, Carreno-Manjarrez, Roberto, Enciso Pelaez, Sandra, Hernandez-Huirache, Hayde, Maldonado Velazquez, Rocio, Orozco, Javier, Rodriguez-Lozano, Ana Luisa, Rojas Pacheco, Omar Ernesto, Suarez Larios, Luz Maria, Vega, Gabriel, Ramirez Miramontes, Julia Veronica, Ruiz Lopez, Ivon Karina, Kamphuis, Sylvia, Schonenberg-Meinema, Dieneke, Concannon, Anthony, Yan, Jaqueline, Jaime, Martha Jarquin, Al Abrawi, Safiya, Vega, Cynthia, Lopez-Benitez, Jorge, Estrella, Amparo Ibanez, Miraval, Tatiana, Dans, Leonia, Kimseng, Karen Joy, Opoka-Winiarska, Violetta, Rutkowska-Sak, Lidia, Smolewska, Elzbieta, Conde, Marta, Guedes, Margarida, del Valle, Enid, Quintero-Del Rio, Ana, Ailioaie, Constantin, Sparchez, Mihaela, Alekseeva, Ekaterina, Keltsev, Vladimir, Al-Mayouf, Sulaiman, Asiri, Abdurhman, Suwairi, Wafaa, Susic, Gordana, Vijatov-Djuric, Gordana, Ang, Elizabeth, Arkachaisri, Thaschawee, Boteanu, Alina-Lucica, Lopez-Robledillo, Juan Carlos, San Ildefonso, Marta Medrano, Modesto, Consuelo, Calvo, Inmaculada, Sotoca-Fernandez, Jorge, Bolt, Isabel, Vilaiyuk, Soamarat, Al-Abadi, Eslam, Baildam, Eileen, Fotis, Lampros, Pain, Clare, Pilkington, Clarissa, Abulaban, Khalid, Barbar-Smiley, Fatima, Binstadt, Bryce, Bohnsack, John, Boneparth, Alexis, Brown, Diane, Chira, Peter, Cron, Randy, Dedeoglu, Fatma, Eberhard, Anne, Gedalia, Abraham, Grom, Alexei, Henrickson, Michael, Hom, Christine, Huggins, Jennifer, Jerath, Rita, Jones, Jordan, Jung, Lawrence, Kingsbury, Daniel, Lai, Jamie, Lovell, Daniel, Nanda, Kabita, Nocton, James, Olson, Judyann, O'Neil, Kathleen, Onel, Karen, Punaro, Lynn, Reiff, Andreas, Rouster-Stevens, Kelly, Ruth, Natasha, Schikler, Ken, Schmidt, Kara Murphy, Schulert, Grant, Shaham, Bracha, Singer, Nora, Smith, Judith, Sundel, Robert, Syverson, Grant, Vega-Fernandez, Patricia, Vehe, Richard, Wagner-Weiner, Linda, Cameto, Juan, Jurado, Rosario, Maldonado, Irama, Org, Paediat Rheumatology Int Trial, Collaborative, Pediat Rheumatology, AII - Inflammatory diseases, Graduate School, Paediatric Infectious Diseases / Rheumatology / Immunology, Brunner, Hermine I., Holland, Michael J., Beresford, Michael W., Ardoin, Stacy P., Appenzeller, Simone, Silva, Clovis A., Flores, Francisco, Goilav, Beatrice, Avar Aydin, Pinar Ozge, Wenderfer, Scott E., Levy, Deborah M., Ravelli, Angelo, Khubchandani, Raju, Avcin, Tadej, Klein-Gitelman, Marisa S., Ruperto, Nicolino, Feldman, Brian M., Ying, Jun, Battagliotti, Cristina, Brusco, Maria Isabel, Cuttica, Rubén, De Cunto, Carmen, Espada, Graciela, Farfan, Maximiliano, Garay, Stella, Marcantoni, Maria, Marcela, Alvarez, Meiorin, Silvia, Rama, Maria Elena, Russo, Ricardo, Torre Walsh, Carolina, Zamparo, Celso, Adib, Navid, Akikusa, Jonathan, Boros, Christina, Lee, Senq J., Mckay, Damien, Piper, Susan, Joos, Rik, Bica, Blanca, Campos, Leonardo, Cavalcanti, André, do Prado, Rogerio, Donner-Maliki, Amanda, Fernandes, Taciana, Fonseca, Adriana, Gasparello de Almeida, Rozana, Guariento, Andressa, Gusman, Catherine, Jusan Fiorot, Fernanda, Knupp Oliveira, Sheila, Len, Claudio, Arruda Campos, Lucia M., Machado, Sandra, Marques, Luciana, Martins de Carvalho, Luciana, Moulin, Rodrigo, Pedroso, Soraya, Pileggi, Gecilmara, Romanelli, Paulo Roberto S., Saad-Magalhaes, Claudia, Sakamoto, Ana, Santos, Maria Carolina, Silva, Marco Felipe, Spelling, Paulo, Sztajnbok, Slavio, Terreri, Maria, Cabral, David, Chédeville, Gaëlle, Ellsworth, Janet, Huber, Adam, Tucker, Lori, Houghton, Kristin, Borzutzky, Arturo, Ladino, Mabel, Norambuena, Ximena, Eraso, Ruth, Mosquera, Angela, Velasquez, Monica, Harjacek, Miroslav, Jelusic, Marija, Coto Hermosilla, Cecilia, Dolezalova, Pavla, Nielsen, Susan, Tineo, Carmen, Alegria, Mauricio, Dressler, Frank, Foell, Dirk, Ganser, Gerd, Hinze, Claa, Hufnagel, Marku, Lutz, Thoma, Trauzeddel, Ralf, Boiu, Sorina, Trachana, Maria, Tsitsami, Elena, Cifuentes, Mayra, Orbán, Ilonka, Aggarwal, Amita, Sawhney, Sujata, Butbul Aviel, Yonatan, Cimaz, Rolando, Maggio, Maria Cristina, Rumba-Rozenfelde, Ingrid, Hashad, Soad, Lim, Sern Chin, Abud, Carlo, Burgos-Vargas, Ruben, Carreño-Manjarrez, Roberto, Enciso Pelaez, Sandra, Hernandez-Huirache, Hayde, Maldonado Velázquez, Rocio, Orozco, Javier, Rodriguez-Lozano, Ana Luisa, Rojas Pacheco, Omar Ernesto, Suárez Larios, Luz Maria, Vega, Gabriel, Ramírez Miramontes, Julia Verónica, Ruíz Lopez, Ivon Karina, Kamphuis, Sylvia, Schonenberg-Meinema, Dieneke, Concannon, Anthony, Yan, Jaqueline, Jarquin Jaime, Martha, Al Abrawi, Safiya, Vega, Cynthia, Lopez-Benitez, Jorge, Ibáñez Estrella, Amparo, Miraval, Tatiana, Dans, Leonia, Kimseng, Karen Joy, Opoka-Winiarska, Violetta, Rutkowska-Sak, Lidia, Smolewska, Elzbieta, Conde, Marta, Guedes, Margarida, del Valle, Enid, Quintero-Del Rio, Ana, Ailioaie, Constantin, Sparchez, Mihaela, Alekseeva, Ekaterina, Keltsev, Vladimir, Al-Mayouf, Sulaiman, Asiri, Abdurhman, Suwairi, Wafaa, Susic, Gordana, Vijatov-Djuric, Gordana, Ang, Elizabeth, Arkachaisri, Thaschawee, Boteanu, Alina-Lucica, Lopez-Robledillo, Juan Carlo, Medrano San Ildefonso, Marta, Modesto, Consuelo, Calvo, Inmaculada, Sotoca-Fernandez, Jorge, Bolt, Isabel, Vilaiyuk, Soamarat, Al-Abadi, Eslam, Baildam, Eileen, Fotis, Lampro, Pain, Clare, Pilkington, Clarissa, Abulaban, Khalid, Barbar-Smiley, Fatima, Binstadt, Bryce, Bohnsack, John, Boneparth, Alexi, Brown, Diane, Chira, Peter, Cron, Randy, Dedeoglu, Fatma, Eberhard, Anne, Gedalia, Abraham, Grom, Alexei, Henrickson, Michael, Hom, Christine, Huggins, Jennifer, Jerath, Rita, Jones, Jordan, Jung, Lawrence, Kingsbury, Daniel, Lai, Jamie, Lovell, Daniel, Nanda, Kabita, Nocton, Jame, Olson, Judyann, O’Neil, Kathleen, Onel, Karen, Punaro, Lynn, Reiff, Andrea, Rouster-Stevens, Kelly, Ruth, Natasha, Schikler, Ken, Murphy Schmidt, Kara, Schulert, Grant, Shaham, Bracha, Singer, Nora, Smith, Judith, Sundel, Robert, Syverson, Grant, Vega-Fernandez, Patricia, Vehe, Richard, Wagner-Weiner, Linda, Cameto, Juan, Jurado, Rosario, Maldonado, Irama, and Pediatrics

Subjects
medicine.medical_specialty, Outcome Assessment, Health Care/methods, Adolescent, Delphi Technique, Antirheumatic Agents/therapeutic use, Severity of Illness Index, Child health, Article, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, Severity of illness, Outcome Assessment, Health Care, medicine, Pediatric nephrology, Humans, Lupus Erythematosus, Systemic, skin and connective tissue diseases, Child, 030203 arthritis & rheumatology, Systemic lupus erythematosus, Lupus erythematosus, Lupus Erythematosus, Receiver operating characteristic, business.industry, Consensus conference, childhood-onset systemic lupus erythematosus, Outcome Assessment, Health Care/methods, medicine.disease, Rheumatology,Systemic lupus erythematosus,autoimmune inflammatory disease, Antirheumatic Agents, Lupus Erythematosus, Systemic/drug therapy, Systemic/drug therapy, business, Algorithms
Abstract

OBJECTIVE: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIc SLE ). METHODS: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRIc SLE and rate a total of 433 unique patient profiles for the presence/absence of CRIc SLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE- CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC] ; range 0-1). RESULTS: During an international consensus conference, unanimous agreement on a definition of CRIc SLE was achieved ; cSLE experts (n = 13) concurred (100%) that the preferred CHILI algorithm considers absolute changes in the cSLE- CRVs. After transformation to a range of 0-100, a CHILI score of ≥54 had outstanding accuracy for identifying CRIc SLE (AUC 0.93, sensitivity 81.1%, and specificity 84.2%). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC ≥0.92, sensitivity ≥93.1%, and specificity ≥73.4%). CONCLUSION: The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.

Published
2019

19. The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort

Author

Bustaffa, Marta, primary, Koné-Paut, Isabelle, additional, Ozen, Seza, additional, Amaryan, Gayane, additional, Papadopoulou-Alataki, Efimia, additional, Gallizzi, Romina, additional, Carrabba, Maria, additional, Aviel, Yonatan Butbul, additional, Cantarini, Luca, additional, Alessio, Maria, additional, Anton, Jordi, additional, Obici, Laura, additional, Gok, Faysal, additional, Batu, Ezgi Deniz, additional, Moreno, Estefania, additional, Brogan, Paul, additional, Trachana, Maria, additional, Simonini, Gabriele, additional, Rigante, Donato, additional, Uziel, Yosef, additional, Insalaco, Antonella, additional, Maggio, Maria Cristina, additional, Ruperto, Nicolino, additional, Gattorno, Marco, additional, and Semerano, L. Rossi, additional

Published
2022
Full Text
View/download PDF

20. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

Author

Grom, Alexei A., Ilowite, Norman T., Pascual, Virginia, Brunner, Hermine I., Martini, Alberto, Lovell, Daniel, Ruperto, Nicolino, Leon, Karolynn, Lheritier, Karine, Abrams, Ken, Cuttica, Ruben, Emminger, Wolfgang, Goffin, Laurence, Joos, Rik, Lauwerys, Bernard, Wouters, Carine, Hilário, Maria Odete Esteves, de Oliveira, Sheila Knupp Feitosa, Len, Claudio, Radominski, Sebastiao, Sztajnbok, Flavio Roberto, Haddad, Elie, Hofer, Michael, Houghton, Kristin, Huber, Adam, Saurenmann, Traudel, Schneider, Rayfel, Tucker, Lori, Bader-Meunier, Brigitte, Desjonqueres, Marine, Fischbach, Michel, Kone-Paut, Isabelle, Marie, Isabelle, Mogenet, Agnes, Mouy, Richard, Quartier, Pierre, Berner, Reinhard, Foeldvari, Ivan, Foell, Dirk, Frosch, Michael, Haas, Johannes-Peter, Horneff, Gerd, Hufnagel, Markus, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Lehmann, Hartwig, Lutz, Thomas, Thon, Angelika, Trauzeddel, Ralf, Tzaribachev, Nikolay, Weibarth-Riedel, Elisabeth, Chrousos, Georgios, Trachana, Maria, Vougiouka, Olga, Constantin, Tamas, Barash, Judith, Berkun, Yackov, Brik, Riva, Harel, Liora, Nahum, Amit, Pade, Shay, Uziel, Yosef, Alessio, Maria, Cimaz, Rolando, Corona, Fabrizia, Gerloni, Valeria, Wulffraat, N. M., Ferrandiz, Manuel, Rutkowska-Sak, Lidia, Alekseeva, Ekaterina, Chasnyk, Vyacheslav, Nasonov, Evgeny, Stanislav, Marina, Anton, Jordi, Calvo, Inmaculada, Gamir, Mari Luz, Robledillos, Juan Carlos, Magnusson, Bo, Erguven, Muferet, Kasapcopur, Ozgur, Ozdogan, Huri, Ozen, Seza, Unsal, Erbil, Chieng, Alice, Foster, Helen, McCann, Liza, Ramanan, Athimalaip, Southwood, Taunton, Wilkinson, Nicholas, Woo, Patricia, Higgins, Gloria Christine, Kingsbury, Daniel, Lopez-Benitez, Jorge, Marzan, Katherine, Morris, Paula, Natter, Marc, and Schikler, Kenneth Noel

Published
2016
Full Text
View/download PDF

21. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

Author

Chalhoub, Nathalie E., Wenderfer, Scott E., Levy, Deborah M., Rouster-Stevens, Kelly, Aggarwal, Amita, Savani, Sonia I., Ruth, Natasha M., Arkachaisri, Thaschawee, Qiu, Tingting, Merritt, Angela, Onel, Karen, Goilav, Beatrice, Khubchandani, Raju P., Deng, Jianghong, Fonseca, Adriana R., Ardoin, Stacy P., Ciurtin, Coziana, Kasapcopur, Ozgur, Jelusic, Marija, Huber, Adam M., Ozen, Seza, Klein-Gitelman, Marisa S., Appenzeller, Simone, Cavalcanti, André, Fotis, Lampros, Lim, Sern Chin, Silva, Rodrigo M., Miramontes, Julia Ramírez, Rosenwasser, Natalie L., Saad-Magalhaes, Claudia [UNESP], Schonenberg-Meinema, Dieneke, Scott, Christiaan, Silva, Clovis A., Enciso, Sandra, Terreri, Maria T., Torres-Jimenez, Alfonso-Ragnar, Trachana, Maria, Al-Mayouf, Sulaiman M., Devarajan, Prasad, Huang, Bin, Brunner, Hermine I., Abulaban, Khalid, Aguiar, Cassyanne, Ahn, Sun-Young, Akoghlanian, Shoghik, Al-Abrawi, Safiya, Aljaberi, Najla, Alperin, Risa, Angeles-Han, Sheila, Ardalan, Kaveh, Bader-Meunier, Brigitte, Balboni, Imelda, Barbar-Smiley, Fatima, Baxter, Sarah, Beary, John, Boneparth, Alexis, Brakeman, Paul, Bridges, John, Burgos-Vargas, Ruben, Cabral, David A., Cameto, Juan, Carter, Caitlin, Chang, Joyce, Chédeville, Gaëlle, Chhakchhuak, Christine, Chiraseveenuprapund, Peter, Cifuentes Alvarado, Mayra, Concannon, Anthony, Cooper, Jennifer, Cron, Randy, De Carvalho, Luciana Martins, De Quattro, Kimberly, De Ranieri, Deirdre, Dizon, Brian, Donnelly Wrigley, Catherine, Duong, Minh Dien, Eberhard, Anne, Ede, Kaleo, Edelheit, Barbara, Edens, Cuoghi, Espada, Graciela, Farhey, Yolanda, Flores, Francisco, Fritz, Deborah, Ganguli, Suhas, Gilbert, Mileka, Gittar, Patsy, Greenbaum, Larry, Grom, Alexei, Gulati, Gaurav, Harry, Onengiya, Hayward, Kristen, Henrickson, Michael, Hersh, Aimee, Hiraki, Linda, Hiskey, Megan, Hoffmann, Sarah, Hollander, Matthew, Hom, Christine, Houk, Lawrence, Houk, J. Brian, Hsieh, Elena W.Y., Hsu, Joyce, Jensen, Paul, Joos, Rik, Jurado, Rosario, Jusan Fiorot, Fernanda, Kallash, Mahmoud, Kamphuis, Sylvia, Keltsev, Vladimir, Khanna, Surabhi, Kim, Susan, Kimseng, Karen Joy, Knight, Andrea, Kunder, Rebecca, Lai, Jamie, Laskin, Benjamin, Lewandowski, Laura, Lim, Lily, Linda, Wagner-Weiner, Lo, Mindy, Lovell, Daniel, Luggen, Michael, Madison, Jacqueline, Mansuri, Asif, Martin, Lorena, Mason, Sherene, Miller, Michael, Mina, Rina, Mohammed, Abdul, Moncrieffe, Halima, Moorthy, Lakshmi, Morgan, Esi, Mosquera, Angela, Muntel, Emily, Muscal, Eyal, Myones, Barry, Nocton, James, Ogbu, Ekemini, Okamura, Daryl, Olson, Judyann, Orrock, Janet, Paim-Marques, Luciana, Pain, Clare, Park, Catherine, Patel, Pooja, Pereira, Maria, Prado, Rogerio do, Radhakrishna, Suhas, Rheault, Michelle, Ridgway, William, Riskalla, Mona, Ronis, Tova, Sadun, Rebecca, Sagcal-Gironella, Anna Carmela, Santos, Maria carolina, Schikler, Kenneth, AL Suwairi, Wafaa, Siddiqi, Nabeela, Silva, Marco Felipe, Singh-Grewal, Davinder, Smitherman, Emily, Smolewska, Elzbieta, Son, Mary Beth, Srinivasalu, Hemalatha, Sule, Sangeeta, Susic, Gordana, Syed, Reema, Thatayatikom, Akaluck, Ting, Tracy, Toth, Mary, Turnier, Jessica, Vashisht, Priyanka, Vega Fernandez, Patricia, Velasquez, Monica, von Scheven, Emily, Wahezi, Dawn, Ware, Avis, Wu, Eveline, Yan, Jacqueline, Yildirim-Toruner, Cagri, Zamparo, Celso, Zhang, Yujuan, Lawson, Erica, Graduate School, Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Inflammatory diseases, University of Cincinnati College of Medicine, Baylor College of Medicine, The Hospital for Sick Children and The University of Toronto, Emory University and Children's Healthcare of Atlanta, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Medical University of South Carolina, KK Women's and Children's Hospital, Cincinnati Children's Hospital Medical Center, Hospital for Special Surgery, Albert Einstein College of Medicine, SRCC Children's Hospital, Capital Medical University and National Center for Children's Health, Universidade Federal do Rio de Janeiro (UFRJ), Nationwide Children's Hospital, University College London, Istanbul University-Cerrahpasa, University of Zagreb School of Medicine, IWK Health Centre and Dalhousie University, Hacettepe University, Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago, Universidade Estadual de Campinas (UNICAMP), Universidade Federal de Pernambuco (UFPE), National and Kapodistian University of Athens, University Teknologi MARA, Instituto Mexicano del Seguro Social, University of Washington and Seattle Children's Hospital, Universidade Estadual Paulista (UNESP), Amsterdam University Medical Center, Red Cross War Memorial Children's Hospital and University of Cape Town, Universidade de São Paulo (USP), Hospital de la Beneficencia Española, Universidade Federal de São Paulo (UNIFESP), National Medical Center La Raza, Aristotle University of Thessaloniki, King Faisal Specialist Hospital and Research Center and Alfaisal University, and University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center

Subjects
Male, medicine.medical_specialty, Adolescent, medicine.drug_class, Immunology, Lupus nephritis, Renal function, Article, Rheumatology, childhood-onset systemic lupus erythematosus, corticosteroids, lupus nephritis, treatment, Internal medicine, Biopsy, Immunology and Allergy, Medicine, Humans, Lupus Erythematosus, Systemic, Dosing, Age of Onset, Child, Glucocorticoids, Retrospective Studies, Kidney, Proteinuria, medicine.diagnostic_test, business.industry, food and beverages, medicine.disease, Lupus Nephritis, Clinical trial, medicine.anatomical_structure, Corticosteroid, Female, medicine.symptom, business
Abstract

Made available in DSpace on 2022-04-28T19:49:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2022-02-01 Arthritis Foundation Institute of Clinical and Translational Sciences Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Diabetes and Digestive and Kidney Diseases National Center for Advancing Translational Sciences Objective: To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood-onset systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN), using consensus formation methodology. Methods: Parameters influencing corticosteroid (CS) dosing were identified (step 1). Data from children with proliferative LN were used to generate patient profiles (step 2). Physicians rated changes in renal and extrarenal childhood-onset SLE activity between 2 consecutive visits and proposed CS dosing (step 3). The SSR was developed using patient profile ratings (step 4), with refinements achieved in a physician focus group (step 5). A second type of patient profile describing the course of childhood-onset SLE for ≥4 months since kidney biopsy was rated to validate the SSR-recommended oral and intravenous (IV) CS dosages (step 6). Patient profile adjudication was based on majority ratings for both renal and extrarenal disease courses, and consensus level was set at 80%. Results: Degree of proteinuria, estimated glomerular filtration rate, changes in renal and extrarenal disease activity, and time since kidney biopsy influenced CS dosing (steps 1 and 2). Considering these parameters in 5,056 patient profile ratings from 103 raters, and renal and extrarenal course definitions, CS dosing rules of the SSR were developed (steps 3–5). Validation of the SSR for up to 6 months post–kidney biopsy was achieved with 1,838 patient profile ratings from 60 raters who achieved consensus for oral and IV CS dosage in accordance with the SSR (step 6). Conclusion: The SSR represents an international consensus on CS dosing for use in patients with childhood-onset SLE and proliferative LN. The SSR is anticipated to be used for clinical care and to standardize CS dosage during clinical trials. University of Cincinnati College of Medicine Baylor College of Medicine The Hospital for Sick Children and The University of Toronto Emory University and Children's Healthcare of Atlanta Sanjay Gandhi Postgraduate Institute of Medical Sciences Medical University of South Carolina KK Women's and Children's Hospital Cincinnati Children's Hospital Medical Center Hospital for Special Surgery Albert Einstein College of Medicine SRCC Children's Hospital Capital Medical University and National Center for Children's Health Universidade Federal do Rio de Janeiro Nationwide Children's Hospital University College London Cerrahpasa Medical School Istanbul University-Cerrahpasa University of Zagreb School of Medicine IWK Health Centre and Dalhousie University Hacettepe University Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago University of Campinas Hospital das Clínicas da Universidade Federal de Pernambuco National and Kapodistian University of Athens University Teknologi MARA Instituto Mexicano del Seguro Social University of Washington and Seattle Children's Hospital São Paulo State University Amsterdam University Medical Center Red Cross War Memorial Children's Hospital and University of Cape Town Universidade de São Paulo Hospital de la Beneficencia Española Universidade Federal de São Paulo National Medical Center La Raza Aristotle University of Thessaloniki King Faisal Specialist Hospital and Research Center and Alfaisal University University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center São Paulo State University CNPq: 303422/2015-7 FAPESP: FAPESP 2015/03756-4 National Institute of Arthritis and Musculoskeletal and Skin Diseases: P30-AR-076316 National Institute of Diabetes and Digestive and Kidney Diseases: P50-DK-096418 National Institute of Arthritis and Musculoskeletal and Skin Diseases: R34-AR-071651 National Center for Advancing Translational Sciences: T32-AR-050958

Published
2021

26. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study

Author

Brunner, I, Hermine Quartier, Pierre Alexeeva, Ekaterina and Constantin, Tamas Kone-Paut, Isabelle Marzan, Katherine and Schneider, Rayfel Wulffraat, Nico M. Chasnyk, Vyacheslav and Tirosh, Irit Kallinich, Tilmann Kuemmerle-Deschner, Jasmin and Wouters, Carine Lauwerys, Bernard Nikishina, Irina Trachana, Maria Vougiouka, Olga Martini, Alberto Lovell, Daniel J. and Levy, Jeremy Vritzali, Eleni Ruperto, Nicolino Paediat Rheumatology Int Trials Or

Abstract

Objective To evaluate the long-term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. Methods At enrollment, patients with active systemic JIA (ages 2 to

Published
2020

27. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results

Author

Brunner, Hermine I., Nanda, Kabita, Toth, Mary, Foeldvari, Ivan, Bohnsack, John, Milojevic, Diana, Rabinovich, C. Egla, Kingsbury, Daniel J., Marzan, Katherine, Chalom, Elizabeth, Horneff, Gerd, Kuester, Rolf-Michael, Dare, Jason A., Trachana, Maria, Jung, Lawrence K., Olson, Judyann, Minden, Kirsten, Quartier, Pierre, Bereswill, Mareike, Kalabic, Jasmina, Kupper, Hartmut, Lovell, Daniel J., Martini, Alberto, Ruperto, Nicolino, Brunner, Hermine I., Nanda, Kabita, Toth, Mary, Foeldvari, Ivan, Bohnsack, John, Milojevic, Diana, Rabinovich, C. Egla, Kingsbury, Daniel J., Marzan, Katherine, Chalom, Elizabeth, Horneff, Gerd, Kuester, Rolf-Michael, Dare, Jason A., Trachana, Maria, Jung, Lawrence K., Olson, Judyann, Minden, Kirsten, Quartier, Pierre, Bereswill, Mareike, Kalabic, Jasmina, Kupper, Hartmut, Lovell, Daniel J., Martini, Alberto, and Ruperto, Nicolino

Abstract

Objective To evaluate safety and effectiveness of adalimumab (ADA) in polyarticular-course juvenile idiopathic arthritis (JIA) in the STRIVE registry. Methods STRIVE enrolled patients with polyarticular-course JIA into 2 arms based on treatment with methotrexate (MTX) alone or ADA with/without MTX (ADA +/- MTX). Adverse events (AEs) per 100 patient-years of observation time were analyzed by registry arm. Patients who entered the registry within 4 weeks of starting MTX or ADA +/- MTX, defined as new users, were evaluated for change in disease activity assessed by the 27-joint Juvenile Arthritis Disease Activity Score with the C-reactive protein level (JADAS-27(CRP)). Results At the 7-year cutoff date (June 1, 2016), data from 838 patients were available (MTX arm n = 301, ADA +/- MTX arm n = 537). The most common AEs were nausea (10.3%), sinusitis (4.7%), and vomiting (4.3%) in the MTX arm and arthritis (3.9%), upper respiratory tract infection (3.5%), sinusitis, tonsillitis, and injection site pain (3.0% each) in the ADA +/- MTX arm. Rates of serious infection were 1.5 events/100 patient-years in the MTX arm and 2.0 events/100 patient-years in the ADA +/- MTX arm. AE and serious AE rates were similar in patients receiving ADA with versus without MTX. No deaths or malignancies were reported. New users in the ADA +/- MTX arm showed a trend toward lower mean JADAS-27(CRP)compared with new users in the MTX arm in the first year of STRIVE. Conclusion The STRIVE registry 7-year interim results support the idea that ADA +/- MTX is well tolerated by most children. Registry median ADA exposure was 2.47 (interquartile range 1.0-3.6) years, with 42% of patients continuing ADA at the 7-year cutoff date.

Published
2020

28. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Fanouriakis, Antonis, Kostopoulou, Myrto, Cheema, Kim, Anders, Hans-Joachim, Aringer, Martin, Bajema, Ingeborg, Boletis, John, Frangou, Eleni, Houssiau, Frédéric, Hollis, Jane, Karras, Adexandre, Marchiori, Francesca, Marks, Stephen D, Moroni, Gabriella, Mosca, Marta, Parodis, Ioannis, Praga, Manuel, Schneider, Matthias, Smolen, Josef S, Tesar, Vladimir, Trachana, Maria, van Vollenhoven, Ronald F, Voskuyl, Alexandre E, Teng, Y K Onno, van Leew, Bernadette, Bertsias, George, Jayne, David, Boumpas, Dimitrios T, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Fanouriakis, Antonis, Kostopoulou, Myrto, Cheema, Kim, Anders, Hans-Joachim, Aringer, Martin, Bajema, Ingeborg, Boletis, John, Frangou, Eleni, Houssiau, Frédéric, Hollis, Jane, Karras, Adexandre, Marchiori, Francesca, Marks, Stephen D, Moroni, Gabriella, Mosca, Marta, Parodis, Ioannis, Praga, Manuel, Schneider, Matthias, Smolen, Josef S, Tesar, Vladimir, Trachana, Maria, van Vollenhoven, Ronald F, Voskuyl, Alexandre E, Teng, Y K Onno, van Leew, Bernadette, Bertsias, George, Jayne, David, and Boumpas, Dimitrios T

Abstract

OBJECTIVE: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). METHODS: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. RESULTS: The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3 g/day or mycophenolic acid (MPA) at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500 mg × 6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5 mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-term maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation

Published
2020

29. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Brunner, Hermine I, Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné-Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M, Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J, Levy, Jeremy, Vritzali, Eleni, Ruperto, Nicolino, Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Brunner, Hermine I, Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné-Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M, Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle-Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J, Levy, Jeremy, Vritzali, Eleni, Ruperto, Nicolino, and Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group

Abstract

OBJECTIVE: To evaluate the long-term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. METHODS: At enrollment, patients with active systemic JIA (ages 2 to <20 years) started open-label canakinumab (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included the adapted American College of Rheumatology (ACR) Pediatric 50/70/90 criteria, the Juvenile Arthritis Disease Activity Score (JADAS), and clinically inactive disease and clinical remission on medication, evaluated by either the JADAS or ACR criteria. RESULTS: Of the 123 patients (70 with fever and 52 without fever [fever status was not reported for 1 patient]), 84 (68.3%) completed the study (median duration 1.8 years). Comparable efficacy (adapted ACR Pediatric 50/70/90/100) was observed by day 15 in both subgroups (60.0%/48.6%/37.1%/24.3% in those with fever and 67.3%/48.1%/34.6%/19.2% in those without fever), and further increased thereafter. By month 6, clinical remission according to the JADAS or the ACR criteria was achieved in 17 (24.3%) and 26 (37.1%), respectively, of patients with fever and 9 (17.3%) and 12 (23.1%), respectively, of patients without fever. Median time to onset of clinical remission according to the JADAS or ACR criteria was 57 and 30 days, respectively, in those with fever, and 58 and 142 days, respectively, in those without fever. An adapted ACR Pediatric 50 response by day 15 was the strongest predictor of achieving clinical remission according to the JADAS (odds ratio [OR] 13 [95% confidence interval (95% CI) 4, 42]; P < 0.0001) or glucocorticoid discontinuation (OR 19 [95% CI 3, 114]; P = 0.002). Of the 71 of 123 patients (57.7%) who received glucocorticoids at study entry, 27 (38.0%) discontinued glucocorticoids and 21 (29.6%) reached a dose of <0.2 mg/kg/day, with no difference between those with and those without fever; 13 patients (10.6%) toler

Published
2020

30. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee

Author

Immuno/reuma patientenzorg, Child Health, Infectieziekten patientenzorg, Infection & Immunity, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Regenerative Medicine and Stem Cells, Onderzoek, Giancane, Gabriella, Swart, Joost F., Castagnola, Elio, Groll, Andreas H., Horneff, Gerd, Huppertz, Hans Iko, Lovell, Daniel J., Wolfs, Tom, Herlin, Troels, Dolezalova, Pavla, Sanner, Helga, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tamas, Vargova, Veronika, Sawhney, Sujata, Rygg, Marite, Oliveira, Sheila K., Cattalini, Marco, Bovis, Francesca, Bagnasco, Francesca, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Cuttica, Ruben, Garay, Stella Maris, Brunner, Jurgen, Emminger, Wolfgang, Appenzeller, Simone, Len, Claudio, Saad Magalhaes, Claudia, Telcharova-Mihaylovska, Albena, Harjacek, Miroslav, Jelusic, Marija, Estmann, Anne, Nielsen, Susan, Herrera Mora, Cristina, Gervais, Elisabeth, Koné-Paut, Isabelle, Quartier, Pierre, Foeldvari, Ivan, Lutz, Thomas, Minden, Kirsten, Tzaribachev, Nikolay, Trachana, Maria, Tsitsami, Elena, Vougiouka, Olga, Orban, Ilonka, Harel, Liora, Hashkes, Philip, Uziel, Yosef, Cimaz, Rolando, Civino, Adele, Consolini, Rita, D'Angelo, Gianfranco, De Benedetti, Fabrizio, Filocamo, Giovanni, Fueri, Elena, Gallizzi, Romina, Maggio, Maria Cristina, Magnolia, Maria Greca, Miniaci, Angela, Montin, Davide, Olivieri, Alma Nunzia, Pastore, Serena, Rigante, Donato, Zulian, Francesco, Rumba-Rozenfelde, Ingrida, Stanevicha, Valda, Panaviene, Violeta, Rodriguez Lozano, Ana Luisa, Rubio-Perez, Nadina, Vega Cornejo, Gabriel, Hoppenreijs, Esther, Kamphuis, Sylvia, Flato, Berit, Nordal, Ellen Berit, Abdwani, Reem, Miraval, Tatiana, Paz Gastanaga, Maria Eliana, Smolewska, Elzbieta, Ailioaie, Constantin, Cochino, Alexis Virgil, Laday, Matilda, Lazar, Calin, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Keltsev, Vladimir, Suwairi, Wafaa Mohammed Saad, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Arkachaisri, Thaschawee, Koskova, Elena, Avcin, Tadej, Ally, Mahmood, Van Rensburg, Christa Janse, Louw, Ingrid, Lopez, Jordi Anton, Boteanu, Alina Lucica, Calvo Penades, Inmaculada, De Inocencio, Jaime, Mesa-Del-Castillo, Pablo, Moreno, Estefania, Remesal, Agustin, Hofer, Michael, Gok, Faysal, Ozen, Seza, Ramanan, Athimalaipet, Pallotti, Chiara, Villa, Luca, Immuno/reuma patientenzorg, Child Health, Infectieziekten patientenzorg, Infection & Immunity, Cluster B, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Regenerative Medicine and Stem Cells, Onderzoek, Giancane, Gabriella, Swart, Joost F., Castagnola, Elio, Groll, Andreas H., Horneff, Gerd, Huppertz, Hans Iko, Lovell, Daniel J., Wolfs, Tom, Herlin, Troels, Dolezalova, Pavla, Sanner, Helga, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tamas, Vargova, Veronika, Sawhney, Sujata, Rygg, Marite, Oliveira, Sheila K., Cattalini, Marco, Bovis, Francesca, Bagnasco, Francesca, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Cuttica, Ruben, Garay, Stella Maris, Brunner, Jurgen, Emminger, Wolfgang, Appenzeller, Simone, Len, Claudio, Saad Magalhaes, Claudia, Telcharova-Mihaylovska, Albena, Harjacek, Miroslav, Jelusic, Marija, Estmann, Anne, Nielsen, Susan, Herrera Mora, Cristina, Gervais, Elisabeth, Koné-Paut, Isabelle, Quartier, Pierre, Foeldvari, Ivan, Lutz, Thomas, Minden, Kirsten, Tzaribachev, Nikolay, Trachana, Maria, Tsitsami, Elena, Vougiouka, Olga, Orban, Ilonka, Harel, Liora, Hashkes, Philip, Uziel, Yosef, Cimaz, Rolando, Civino, Adele, Consolini, Rita, D'Angelo, Gianfranco, De Benedetti, Fabrizio, Filocamo, Giovanni, Fueri, Elena, Gallizzi, Romina, Maggio, Maria Cristina, Magnolia, Maria Greca, Miniaci, Angela, Montin, Davide, Olivieri, Alma Nunzia, Pastore, Serena, Rigante, Donato, Zulian, Francesco, Rumba-Rozenfelde, Ingrida, Stanevicha, Valda, Panaviene, Violeta, Rodriguez Lozano, Ana Luisa, Rubio-Perez, Nadina, Vega Cornejo, Gabriel, Hoppenreijs, Esther, Kamphuis, Sylvia, Flato, Berit, Nordal, Ellen Berit, Abdwani, Reem, Miraval, Tatiana, Paz Gastanaga, Maria Eliana, Smolewska, Elzbieta, Ailioaie, Constantin, Cochino, Alexis Virgil, Laday, Matilda, Lazar, Calin, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Keltsev, Vladimir, Suwairi, Wafaa Mohammed Saad, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Arkachaisri, Thaschawee, Koskova, Elena, Avcin, Tadej, Ally, Mahmood, Van Rensburg, Christa Janse, Louw, Ingrid, Lopez, Jordi Anton, Boteanu, Alina Lucica, Calvo Penades, Inmaculada, De Inocencio, Jaime, Mesa-Del-Castillo, Pablo, Moreno, Estefania, Remesal, Agustin, Hofer, Michael, Gok, Faysal, Ozen, Seza, Ramanan, Athimalaipet, Pallotti, Chiara, and Villa, Luca

Published
2020

32. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis

Author

Fanouriakis, Antonis, primary, Kostopoulou, Myrto, additional, Cheema, Kim, additional, Anders, Hans-Joachim, additional, Aringer, Martin, additional, Bajema, Ingeborg, additional, Boletis, John, additional, Frangou, Eleni, additional, Houssiau, Frederic A, additional, Hollis, Jane, additional, Karras, Adexandre, additional, Marchiori, Francesca, additional, Marks, Stephen D, additional, Moroni, Gabriella, additional, Mosca, Marta, additional, Parodis, Ioannis, additional, Praga, Manuel, additional, Schneider, Matthias, additional, Smolen, Josef S, additional, Tesar, Vladimir, additional, Trachana, Maria, additional, van Vollenhoven, Ronald F, additional, Voskuyl, Alexandre E, additional, Teng, Y K Onno, additional, van Leew, Bernadette, additional, Bertsias, George, additional, Jayne, David, additional, and Boumpas, Dimitrios T, additional

Published
2020
Full Text
View/download PDF

37. The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Author

Pratsidou-Gertsi, Polyxeni Trachana, Maria Kanakoudi-Tsakalidou, Florence Tsitsami, Elena Tsinti, Maria Vougiouka, Olga and Siamopoulou, Antigoni Alfantaki, Sapfo Stavrakidou, Maria and Consolaro, Alessandro Bovis, Francesca Ruperto, Nicolino and Paediat Rheumatology Int Trials

Abstract

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Greek language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographics, clinical data, and the JAMAR from 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). The Greek JAMAR was fully cross-culturally adapted with two forward and three backward translations. A total of 272 JIA patients (5.9% systemic, 57.7% oligoarticular, 21.3% RF negative poly-arthritis, 15.1% other categories), and 100 healthy children were enrolled in all centres. The JAMAR components discriminated well-healthy subjects from JIA patients; notably, there was no significant difference between healthy subjects and their affected peers in psychosocial quality of life and school-related items. All JAMAR components revealed good psychometric performances. In conclusion, the Greek version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and in clinical research.

Published
2018

38. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity

Author

Panousis, Nikolaos I, primary, Bertsias, George K, additional, Ongen, Halit, additional, Gergianaki, Irini, additional, Tektonidou, Maria G, additional, Trachana, Maria, additional, Romano-Palumbo, Luciana, additional, Bielser, Deborah, additional, Howald, Cedric, additional, Pamfil, Cristina, additional, Fanouriakis, Antonis, additional, Kosmara, Despoina, additional, Repa, Argyro, additional, Sidiropoulos, Prodromos, additional, Dermitzakis, Emmanouil T, additional, and Boumpas, Dimitrios T, additional

Published
2019
Full Text
View/download PDF

41. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

Author

Consolaro, Alessandro, primary, Giancane, Gabriella, additional, Alongi, Alessandra, additional, van Dijkhuizen, Evert Hendrik Pieter, additional, Aggarwal, Amita, additional, Al-Mayouf, Sulaiman M, additional, Bovis, Francesca, additional, De Inocencio, Jaime, additional, Demirkaya, Erkan, additional, Flato, Berit, additional, Foell, Dirk, additional, Garay, Stella Maris, additional, Lazăr, Călin, additional, Lovell, Daniel J, additional, Montobbio, Carolina, additional, Miettunen, Paivi, additional, Mihaylova, Dimitrina, additional, Nielsen, Susan, additional, Orban, Ilonka, additional, Rumba-Rozenfelde, Ingrida, additional, Magalhães, Claudia Saad, additional, Shafaie, Nahid, additional, Susic, Gordana, additional, Trachana, Maria, additional, Wulffraat, Nico, additional, Pistorio, Angela, additional, Martini, Alberto, additional, Ruperto, Nicolino, additional, Ravelli, Angelo, additional, Abdwani, Reem, additional, Aghighi, Yahya, additional, Aiche, Maya-Feriel, additional, Ailioaie, Constantin, additional, Aktay Ayaz, Nuray, additional, Al-Abrawi, Safiya, additional, Alexeeva, Ekaterina, additional, Anton, Jordi, additional, Apostol, Adriana, additional, Arguedas, Olga, additional, Avcin, Tadej, additional, Barone, Patrizia, additional, Berntson, Lillemor, additional, Boteanu, Alina Lucica, additional, Boyko, Yaryna, additional, Burgos-Vargas, Ruben, additional, Calvo Penades, Inmaculada, additional, Chédeville, Gaëlle, additional, Cimaz, Rolando, additional, Civino, Adele, additional, Consolini, Rita, additional, Constantin, Tamas, additional, Cuttica, Ruben, additional, Dallos, Tomas, additional, Martin, Neil, additional, Magni Manzoni, Silvia, additional, De Cunto, Carmen, additional, Dolezalova, Pavla, additional, Ekelund, Maria, additional, El Miedany, Yasser, additional, Espada, Graciela, additional, Estmann Christensen, Anne, additional, Foeldvari, Ivan, additional, Gallizzi, Romina, additional, Ganser, Gerd, additional, Gerloni, Valeria, additional, Haas, Johannes-Peter, additional, Harel, Liora, additional, Harjacek, Miroslav, additional, Hashad, Soad, additional, Herlin, Troels, additional, Herrera, Cristina, additional, Hofer, Michael, additional, Holzinger, Dirk, additional, Horneff, Gerd, additional, Huppertz, Hans-Iko, additional, Iagăru, Nicolae, additional, Ibanez Estrella, Amparo, additional, Ioseliani, Maka, additional, Joos, Rik, additional, Knupp Oliveira, Sheila, additional, Kamphuis, Sylvia, additional, Kasapcopur, Ozgur, additional, Katsicas, Maria Martha, additional, Khubchandani, Raju, additional, Kondi, Anuela, additional, Kröger, Liisa, additional, La Torre, Francesco, additional, Laday, Matilda, additional, Lahdenne, Pekka, additional, Maggio, Maria Cristina, additional, Magnolia, Maria Greca, additional, Malagon, Clara, additional, Malin, Merja, additional, Martino, Silvana, additional, Melo-Gomes, Jose Antonio, additional, Mesa-del-Castillo, Pablo, additional, Militaru, Andrea, additional, Minden, Kirsten, additional, Miniaci, Angela, additional, Moradinejad, Mohammad Hasan, additional, Morel Ayala, Zoilo, additional, Nikishina, Irina, additional, Norambuena, Ximena, additional, Nordal, Ellen Berit, additional, Pagava, Karaman, additional, Panaviene, Violeta, additional, Pastore, Serena, additional, Pieropan, Sara, additional, Podda, Rosa Anna, additional, Pruunsild, Chris, additional, Putto-Laurila, Anne, additional, Quartier, Pierre, additional, Remesal, Agustin, additional, Rigante, Donato, additional, Ringold, Sarah, additional, Rutkowska-Sak, Lidia, additional, Rygg, Marite, additional, Saurenmann, Rotraud Katharina, additional, Sawhney, Sujata, additional, Scott, Christiaan, additional, Shiari, Reza, additional, Smolewska, Elzbieta, additional, Sozeri, Betul, additional, Swart, Joost Frans, additional, Sztajnbok, Flavio, additional, Torcoletti, Marta, additional, Tsitsami, Elena, additional, Tzaribachev, Nikolay, additional, Unsal, Erbil, additional, Uziel, Yosef, additional, Vähäsalo, Paula, additional, Varbanova, Boriana, additional, Vargova, Veronika, additional, Vesely, Richard, additional, Vijatov-Djuric, Gordana, additional, Vilaiyuk, Soamarat, additional, Vojinovic, Jelena, additional, Vougiouka, Olga, additional, Weiss, Pamela, additional, and Wouters, Carine, additional

Published
2019
Full Text
View/download PDF

43. In silico validation of the autoinflammatory disease damage index

Author

Ter Haar, Nienke M., Van Delft, Amber Laetitia Justine, Annink, Kim Valerie, Van Stel, Henk, Al-Mayouf, Sulaiman M., Amaryan, Gayane, Anton, Jordi, Barron, Karyl S., Benseler, Susanne, Brogan, Paul A., Cantarini, Luca, Cattalini, Marco, Cochino, Alexis Virgil, De Benedetti, Fabrizio, Dedeoglu, Fatma, De Jesus, Adriana Almeida, Demirkaya, Erkan, Dolezalova, Pavla, Durrant, Karen L., Fabio, Giovanna, Gallizzi, Romina, Goldbach-Mansky, Raphaela, Hachulla, Eric, Hentgen, Veronique, Herlin, Troels, Hofer, Michaël, Hoffman, Hal M., Insalaco, Antonella, Jansson, Annette F., Kallinich, Tilmann, Kone-Paut, Isabelle, Kozlova, Anna, Kuemmerle-Deschner, Jasmin Beate, Lachmann, Helen J., Laxer, Ronald M., Martini, Alberto, Nielsen, Susan, Nikishina, Irina, Ombrello, Amanda K., Özen, Seza, Papadopoulou-Alataki, Efimia, Quartier, Pierre, Rigante, Donato, Russo, Ricardo, Simon, Anna, Trachana, Maria, Uziel, Yosef, Ravelli, Angelo, Schulert, Grant, Gattorno, Marco, Frenkel, Joost, Ter Haar, Nienke M., Van Delft, Amber Laetitia Justine, Annink, Kim Valerie, Van Stel, Henk, Al-Mayouf, Sulaiman M., Amaryan, Gayane, Anton, Jordi, Barron, Karyl S., Benseler, Susanne, Brogan, Paul A., Cantarini, Luca, Cattalini, Marco, Cochino, Alexis Virgil, De Benedetti, Fabrizio, Dedeoglu, Fatma, De Jesus, Adriana Almeida, Demirkaya, Erkan, Dolezalova, Pavla, Durrant, Karen L., Fabio, Giovanna, Gallizzi, Romina, Goldbach-Mansky, Raphaela, Hachulla, Eric, Hentgen, Veronique, Herlin, Troels, Hofer, Michaël, Hoffman, Hal M., Insalaco, Antonella, Jansson, Annette F., Kallinich, Tilmann, Kone-Paut, Isabelle, Kozlova, Anna, Kuemmerle-Deschner, Jasmin Beate, Lachmann, Helen J., Laxer, Ronald M., Martini, Alberto, Nielsen, Susan, Nikishina, Irina, Ombrello, Amanda K., Özen, Seza, Papadopoulou-Alataki, Efimia, Quartier, Pierre, Rigante, Donato, Russo, Ricardo, Simon, Anna, Trachana, Maria, Uziel, Yosef, Ravelli, Angelo, Schulert, Grant, Gattorno, Marco, and Frenkel, Joost

Published
2018

44. In silico validation of the autoinflammatory disease damage index

Author

Infection & Immunity, Child Health, CTI Vastert, MS Neonatologie, Brain, JC onderzoeksprogramma Methodologie, Other research (not in main researchprogram), Verplegingswetenschap, Arts-assistenten Kinderen, Ter Haar, Nienke M., Van Delft, Amber Laetitia Justine, Annink, Kim Valerie, Van Stel, Henk, Al-Mayouf, Sulaiman M., Amaryan, Gayane, Anton, Jordi, Barron, Karyl S., Benseler, Susanne, Brogan, Paul A., Cantarini, Luca, Cattalini, Marco, Cochino, Alexis Virgil, De Benedetti, Fabrizio, Dedeoglu, Fatma, De Jesus, Adriana Almeida, Demirkaya, Erkan, Dolezalova, Pavla, Durrant, Karen L., Fabio, Giovanna, Gallizzi, Romina, Goldbach-Mansky, Raphaela, Hachulla, Eric, Hentgen, Veronique, Herlin, Troels, Hofer, Michaël, Hoffman, Hal M., Insalaco, Antonella, Jansson, Annette F., Kallinich, Tilmann, Kone-Paut, Isabelle, Kozlova, Anna, Kuemmerle-Deschner, Jasmin Beate, Lachmann, Helen J., Laxer, Ronald M., Martini, Alberto, Nielsen, Susan, Nikishina, Irina, Ombrello, Amanda K., Özen, Seza, Papadopoulou-Alataki, Efimia, Quartier, Pierre, Rigante, Donato, Russo, Ricardo, Simon, Anna, Trachana, Maria, Uziel, Yosef, Ravelli, Angelo, Schulert, Grant, Gattorno, Marco, Frenkel, Joost, Infection & Immunity, Child Health, CTI Vastert, MS Neonatologie, Brain, JC onderzoeksprogramma Methodologie, Other research (not in main researchprogram), Verplegingswetenschap, Arts-assistenten Kinderen, Ter Haar, Nienke M., Van Delft, Amber Laetitia Justine, Annink, Kim Valerie, Van Stel, Henk, Al-Mayouf, Sulaiman M., Amaryan, Gayane, Anton, Jordi, Barron, Karyl S., Benseler, Susanne, Brogan, Paul A., Cantarini, Luca, Cattalini, Marco, Cochino, Alexis Virgil, De Benedetti, Fabrizio, Dedeoglu, Fatma, De Jesus, Adriana Almeida, Demirkaya, Erkan, Dolezalova, Pavla, Durrant, Karen L., Fabio, Giovanna, Gallizzi, Romina, Goldbach-Mansky, Raphaela, Hachulla, Eric, Hentgen, Veronique, Herlin, Troels, Hofer, Michaël, Hoffman, Hal M., Insalaco, Antonella, Jansson, Annette F., Kallinich, Tilmann, Kone-Paut, Isabelle, Kozlova, Anna, Kuemmerle-Deschner, Jasmin Beate, Lachmann, Helen J., Laxer, Ronald M., Martini, Alberto, Nielsen, Susan, Nikishina, Irina, Ombrello, Amanda K., Özen, Seza, Papadopoulou-Alataki, Efimia, Quartier, Pierre, Rigante, Donato, Russo, Ricardo, Simon, Anna, Trachana, Maria, Uziel, Yosef, Ravelli, Angelo, Schulert, Grant, Gattorno, Marco, and Frenkel, Joost

Published
2018

45. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study.

Author

Brunner, Hermine I., Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné‐Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M., Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle‐Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J., and Levy, Jeremy

Subjects
THERAPEUTIC use of monoclonal antibodies, SUBCUTANEOUS injections, CLINICAL trials, COMPARATIVE studies, CONFIDENCE intervals, FEVER, GLUCOCORTICOIDS, MONOCLONAL antibodies, JUVENILE idiopathic arthritis, TREATMENT effectiveness, DISEASE remission, DESCRIPTIVE statistics, ODDS ratio
Abstract

Objective: To evaluate the long‐term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. Methods: At enrollment, patients with active systemic JIA (ages 2 to <20 years) started open‐label canakinumab (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included the adapted American College of Rheumatology (ACR) Pediatric 50/70/90 criteria, the Juvenile Arthritis Disease Activity Score (JADAS), and clinically inactive disease and clinical remission on medication, evaluated by either the JADAS or ACR criteria. Results: Of the 123 patients (70 with fever and 52 without fever [fever status was not reported for 1 patient]), 84 (68.3%) completed the study (median duration 1.8 years). Comparable efficacy (adapted ACR Pediatric 50/70/90/100) was observed by day 15 in both subgroups (60.0%/48.6%/37.1%/24.3% in those with fever and 67.3%/48.1%/34.6%/19.2% in those without fever), and further increased thereafter. By month 6, clinical remission according to the JADAS or the ACR criteria was achieved in 17 (24.3%) and 26 (37.1%), respectively, of patients with fever and 9 (17.3%) and 12 (23.1%), respectively, of patients without fever. Median time to onset of clinical remission according to the JADAS or ACR criteria was 57 and 30 days, respectively, in those with fever, and 58 and 142 days, respectively, in those without fever. An adapted ACR Pediatric 50 response by day 15 was the strongest predictor of achieving clinical remission according to the JADAS (odds ratio [OR] 13 [95% confidence interval (95% CI) 4, 42]; P < 0.0001) or glucocorticoid discontinuation (OR 19 [95% CI 3, 114]; P = 0.002). Of the 71 of 123 patients (57.7%) who received glucocorticoids at study entry, 27 (38.0%) discontinued glucocorticoids and 21 (29.6%) reached a dose of <0.2 mg/kg/day, with no difference between those with and those without fever; 13 patients (10.6%) tolerated a sustained canakinumab dose reduction to 2 mg/kg every 4 weeks. No new safety findings were observed. Conclusion: Canakinumab provided rapid and sustained improvement of active systemic JIA irrespective of the presence of fever at treatment initiation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis

Author

Consolaro, Alessandro, Dijkhuizen, Pieter, Espada, Graciela, Varbanova, Boriana, Oliveira, Sheila, Miettunen, Paivi, Chedeville, Gaelle, Hofer, Michael, Dolezalova, Pavla, Foeldvari, Ivan, Horneff, Gerd, Estmann, Anne, Pruunsild, Chris, Merino, Rosa, Penades, Inmaculada Calvo, Del Castillo, Pablo Mesa, Lahdenne, Pekka, Ioseliani, Maka, Trachana, Maria, Vougiouka, Olga, Harjacek, Miroslav, Orban, Ilonka, Constantin, Tamas, Shafaie, Nahid, Panaviene, Violeta Vladislava, Rygg, Marite, Smolewska, Elzbieta, Gomes, Jose Antonio Melo, Vojinovic, Jelena, Alexeeva, Ekaterina, Avcin, Tadej, Vargova, Veronika, Ayaz, Nuray Aktay, Ozgur Kasapcopur, Boyko, Yaryna, Ringold, Sarah, Rinaldi, Mariangela, Garrone, Marco, Ruperto, Nicolino, and Ravelli, Angelo

Subjects
juvenile idiopathic arthritis (JIA) and outcome measures, Disease Activity
Published
2017

47. In silico validation of the Autoinflammatory Disease Damage Index

Author

ter Haar, Nienke M, primary, van Delft, Amber Laetitia Justine, additional, Annink, Kim Valerie, additional, van Stel, Henk, additional, Al-Mayouf, Sulaiman M, additional, Amaryan, Gayane, additional, Anton, Jordi, additional, Barron, Karyl S, additional, Benseler, Susanne, additional, Brogan, Paul A, additional, Cantarini, Luca, additional, Cattalini, Marco, additional, Cochino, Alexis-Virgil, additional, de Benedetti, Fabrizio, additional, Dedeoglu, Fatma, additional, de Jesus, Adriana Almeida, additional, Demirkaya, Erkan, additional, Dolezalova, Pavla, additional, Durrant, Karen L, additional, Fabio, Giovanna, additional, Gallizzi, Romina, additional, Goldbach-Mansky, Raphaela, additional, Hachulla, Eric, additional, Hentgen, Veronique, additional, Herlin, Troels, additional, Hofer, Michaël, additional, Hoffman, Hal M, additional, Insalaco, Antonella, additional, Jansson, Annette F, additional, Kallinich, Tilmann, additional, Kone-Paut, Isabelle, additional, Kozlova, Anna, additional, Kuemmerle-Deschner, Jasmin Beate, additional, Lachmann, Helen J, additional, Laxer, Ronald M, additional, Martini, Alberto, additional, Nielsen, Susan, additional, Nikishina, Irina, additional, Ombrello, Amanda K, additional, Özen, Seza, additional, Papadopoulou-Alataki, Efimia, additional, Quartier, Pierre, additional, Rigante, Donato, additional, Russo, Ricardo, additional, Simon, Anna, additional, Trachana, Maria, additional, Uziel, Yosef, additional, Ravelli, Angelo, additional, Schulert, Grant, additional, Gattorno, Marco, additional, and Frenkel, Joost, additional

Published
2018
Full Text
View/download PDF

48. Genomic dissection of Systemic Lupus Erythematosus: Distinct Susceptibility, Activity and Severity Signatures

Author

Panousis, Nikolaos I., primary, Bertsias, George, additional, Ongen, Halit, additional, Gergianaki, Irini, additional, Tektonidou, Maria, additional, Trachana, Maria, additional, Romano-Palumbo, Luciana, additional, Bielser, Deborah, additional, Howald, Cedric, additional, Pamfil, Cristina, additional, Fanouriakis, Antonis, additional, Kosmara, Despoina, additional, Repa, Argyro, additional, Sidiropoulos, Prodromos, additional, Dermitzakis, Emmanouil T., additional, and Boumpas, Dimitrios T., additional

Published
2018
Full Text
View/download PDF

49. Phenotypic Variability and Disparities in Treatment and Outcomes of Childhood Arthritis Throughout the World: Results from the EPOCA Study

Author

Ravelli, Angelo, primary, Consolaro, Alessandro, additional, Giancane, Gabriella, additional, Alongi, Alessandra, additional, Pieter van Dijkhuizen, Evert Hendrik, additional, Aggarwal, Amita, additional, Al-Mayouf, Sulaiman M., additional, Bovis, Francesca, additional, De Inocencio, Jaime, additional, Demirkaya, Erkan, additional, Flato, Berit, additional, Foell, Dirk, additional, Maris Garay, Stella, additional, Lazăr, Călin, additional, Lovell, Daniel J., additional, Montobbio, Carolina, additional, Miettunen, Paivi, additional, Mihaylova, Dimitrina, additional, Nielsen, Susan, additional, Orban, Ilonka, additional, Rumba-Rozenfelde, Ingrida, additional, Saad Magalhaes, Claudia, additional, Shafaie, Nahid, additional, Susic, Gordana, additional, Trachana, Maria, additional, Wulffraat, Nico, additional, Pistorio, Angela, additional, Martini, Alberto, additional, Ruperto, Nicolino, additional, and Organisation (PRINTO), Paediatric Rheumatology Internation, additional

Published
2018
Full Text
View/download PDF

50. A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry

Author

Papa, Riccardo, Doglio, Matteo, Lachmann, Helen J., Ozen, Seza, Frenkel, Joost, Simon, Anna, Neven, Bénédicte, Kuemmerle-Deschner, Jasmin B., Ozgodan, Huri, Caorsi, Roberta, Federici, Silvia, Finetti, Martina, Trachana, Maria, Brunner, Jurgen, Bezrodnik, Liliana, Pinedo Gago, Mari Carmen, Maggio, Maria Cristina, Tsitsami, Elena, Al Suwairi, Wafaa, Espada, Graciela, Shcherbina, Anna, Aksu, Guzide, Ruperto, Nicolino, Martini, Alberto, Ceccherini, Isabella, Gattorno, Marco, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Project, Papa, Riccardo, Doglio, Matteo, Lachmann, Helen J., Ozen, Seza, Frenkel, Joost, Simon, Anna, Neven, Bénédicte, Kuemmerle-Deschner, Jasmin B., Ozgodan, Huri, Caorsi, Roberta, Federici, Silvia, Finetti, Martina, Trachana, Maria, Brunner, Jurgen, Bezrodnik, Liliana, Pinedo Gago, Mari Carmen, Maggio, Maria Cristina, Tsitsami, Elena, Al Suwairi, Wafaa, Espada, Graciela, Shcherbina, Anna, Aksu, Guzide, Ruperto, Nicolino, Martini, Alberto, Ceccherini, Isabella, Gattorno, Marco, and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Project

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results